You do realize that AMRN is tying up every source for FDA approved raw materials to make a generic Vascepa !!! They have all the patents in place,now they are blocking entry to generics by contracting with all the sources of the chemicals.
Who needs the NCE...it seems redundant.
Generic Vascepa? LOL! The company is in month five of marketing Vascepa and you think anyone in their right mind is concerned about "generic" Vascepa. I mean the entire fish oil market is getting so over crowded as it is it's a joke. The last thing anyone is concerned with right now is generic Vascepa. Like cornering the buggy whip market in 1900..
Last time BASF acquired Pronova, Amarin jumped 7.72% during the trading session.
Cost of API going down 50% is a major improvement AND a point blank shot at the shorts' rhetoric saying that margins are poor...
I suspect this will be announced by management at the CC as a mitigating factor for the poor sales number they could report. I expect the number to be quite low despite good script growth number on the back of promotion / coupons. As the story unfold, Amarin could be a monster in the making.
Shorts, better cover soon ;)